Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Some of pharma’s biggest players — including Merck, Amgen, Abbvie, and Gilead — formed an alliance to fight looming M&A reforms.
Macy’s is going less colosseum and more cozy in a cost-cutting shift away from large locations in malls and into small-format stores.
Blue Origin is expected to back out of plans to build a commercial space station in conjunction with corporate partners.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
In an interview with Bloomberg, CEO Brian Chesky laid out how Airbnb has been rocked by user dissatisfaction and tighter regulation.
Despite widespread monetary rain clouds pushing up the cost of beer and food, drinkers are showing up in record numbers to Oktoberfest.
After five months, the writers strike finally came to an end, but the new pact may mean fewer new shows, meaning fewer jobs.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
There’s been this little obstacle standing in the way of a functioning nationwide marijuana market: the law.
The weight loss drug market could be worth $100 billion in the next few years. Naturally, other companies want in.
The EU’s antitrust investigation claims that China is artificially flooding the market with cheap EVs via enormous state subsidies.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.